NCT02229253已完成不适用
Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 112
- 试验地点
- 1
- 主要终点
- Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice
研究概览
简要总结
Patients with prostate cancer and a history of cardiovascular disease treated with degarelix for their prostate cancer, will be followed for a period of one year. In this real-life, non-interventional trial, any cardiovascular events occurring during degarelix therapy will be documented.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Patients with prostate cancer and a history of cardiovascular disease, prescribed degarelix for the treatment of their prostate cancer
排除标准
- •Patients who have received a form of androgen deprivation therapy for their prostate cancer, during the 12 months preceding this study are excluded
- •Planned intermittent or short-term (< 12 months) degarelix treatment
- •Planned addition of, or switch to another form of androgen deprivation therapy during the study
研究组 & 干预措施
Degarelix
Treatment according to standard clinical practice.
干预措施: degarelix (Drug)
结局指标
主要结局
Cardiovascular event rate in hormone naïve prostate cancer patients with cardiovascular comorbidity at baseline, treated with degarelix in daily practice
时间窗: Up to 1 year
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)Prostate NeoplasmNCT01630967British Columbia Cancer Agency40
终止
2 期
A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate CancerProstatic NeoplasmsNCT01545882Ottawa Hospital Research Institute5
进行中（未招募）
不适用
Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate CancerCardiotoxicityDrug-Related Side Effects and Adverse ReactionsCardiovascular DiseasesProstate CancerNCT05096338Abramson Cancer Center at Penn Medicine200
进行中（未招募）
2 期
RElugolix VErsus LeUprolide Cardiac TrialNCT05320406Emory University94
终止
2 期
Study Investigating the Long-Term Safety and Tolerability of Repeated Doses of Degarelix in Prostate Cancer PatientsProstate CancerNCT00245466Ferring Pharmaceuticals88